Shares of Pfizer Inc. moved higher on Monday following regulatory news that provides a near-term catalyst for the pharmaceutical giant's expanding oncology portfolio. The U.S. Food and Drug Administration has accepted for priority review a supplemental application for Padcev (enfortumab vedotin-ejfv), developed in partnership with Astellas Pharma, for the treatment of muscle-invasive bladder cancer. The agency has assigned a Prescription Drug User Fee Act (PDUFA) action date of August 17, 2026.
The stock closed the session up approximately 0.8% at $27.78, as the market digested the development. The news arrives at a critical juncture for Pfizer, which is navigating a strategic reset as revenue from its COVID-19 products continues to decline and several older blockbuster drugs face loss of exclusivity. The company is scheduled to report its first-quarter financial results on May 5, offering investors a fresh look at its progress.
Oncology Pipeline Offers Near-Term Catalyst
The priority review for Padcev, in combination with Merck's Keytruda (pembrolizumab), targets a significant expansion of its use. The companies are seeking approval for the treatment of patients with muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy, as well as for those who are cisplatin-eligible. This broadened label is supported by late-stage clinical trial data demonstrating a 47% reduction in the risk of disease recurrence, progression, or death, alongside a 35% lower risk of death compared to standard chemotherapy.
Jeff Legos, Pfizer's Chief Oncology Officer, characterized the combination as a potential "meaningful" shift in the treatment paradigm for this aggressive cancer, pending regulatory endorsement. The FDA's priority review designation shortens the standard review timeline, indicating the agency views the application as one that could provide a significant improvement in safety or effectiveness.
Financial Reset and 2026 Guidance
All eyes are on Pfizer's upcoming earnings report to assess its trajectory against full-year 2026 revenue guidance of $59.5 billion to $62.5 billion. This forecast already incorporates an estimated $1.5 billion headwind from lost exclusivity on key drugs and anticipates approximately $5 billion in revenue from its COVID-19 portfolio, a fraction of its pandemic-era peak. The company has signaled an aggressive clinical push, with plans to initiate roughly 20 pivotal studies this year that could yield new approvals before year-end.
The financial picture is a mix of challenges and potential. The company recorded a substantial $4.4 billion write-down on unused COVID-19 inventory last year, raising questions about dividend coverage. However, some analysts point to a deep late-stage pipeline and a historically low valuation as reasons for long-term optimism, albeit on a slower growth path than during the pandemic.
The High-Stakes Obesity Arena
Beyond oncology, Pfizer's most significant long-term growth bet resides in the lucrative obesity market. The company is focusing on GLP-1 receptor agonists, a class of drugs that mimic gut hormones to curb appetite and improve blood sugar control. Following its acquisition of Metsera last year, Pfizer is advancing its candidates, including a once-monthly injectable, PF-3944.
Data released in February showed PF-3944 prompted weight loss of up to 12.3% over 28 weeks in non-diabetic patients. However, tolerability remains a noted concern, with Gabelli Funds' Daniel Barasa calling the data "good, but not category-defining." Reuters has reported that Pfizer is targeting its first obesity drug approval for 2028. The competitive landscape is fierce, with Eli Lilly and Novo Nordisk dominating the market. Analysts project the global obesity drug sector could reach $150 billion in annual sales within a decade.
Pfizer did secure a commercial win in March when China approved Xianweiying, its once-weekly GLP-1 therapy, for long-term weight management. Its primary obesity candidates for the U.S. market, however, remain in clinical trials. The path has seen setbacks, including the discontinuation of the oral candidate danuglipron last year due to liver safety concerns.
Post-COVID Reality and Valuation
The transition away from pandemic-driven revenue is stark. Earlier this month, Pfizer and partner BioNTech terminated a major U.S. trial for an updated COVID-19 vaccine in adults aged 50 to 64, citing slow patient recruitment—a clear sign of shifting demand dynamics.
Currently, Pfizer stock trades at about 13.7 times earnings and offers a dividend yield of approximately 6.2%, based on its current share price and a quarterly dividend of $0.43. The central investment thesis now hinges on whether the company's pipeline—spanning oncology, obesity, and other areas—can generate sufficient growth to overcome the looming patent cliff and generic competition. The next significant milestone for investors will be the first-quarter earnings report on May 5.
